Global Chemotherapy Induced Anemia Market
Global Chemotherapy Induced Anemia Market

Chemotherapy Induced Anemia Comprehensive Study by Drug Type (Androxy Oral, Epoetin Alfa Injection, Epogen Injection, Procrit Injection, Aranesp injection, Others), Type of Anemia (Mild Anemia, Moderate Anemia, Severe Anemia, Life-threatening Anemia), Treatment Type (Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation, RBC Transfusions), End User (Hospitals, Ambulatory Surgical Centers, Multispecialty Clinics, Cancer Research Centers, Cancer Rehabilitation Centers) Players and Region - Global Market Outlook to 2026

Chemotherapy Induced Anemia Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 243 Pages 197 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Chemotherapy Induced Anemia Market Scope
Chemotherapy is the cancer treatment given to patients with different forms of cancer. Anemia is a condition of a decrease in the total amount of red blood cells or hemoglobin in the blood. Hemoglobin is an essential part of the red blood cells and binds oxygen. In the case of low or abnormal red blood cells, the cells in the body will not receive the appropriate amount of oxygen. Chemotherapy-induced anemia is primarily due to chemotherapy, which delays or limits the progression of treatment, and contributes significantly to both fatigue and diminished quality of life. In the United States, patients with chemotherapy-induced anemia are treated with erythropoiesis-stimulating agents namely epoetin & darbepoetin.

The Chemotherapy Induced Anemia market study is segmented and major geographies with country level break-up.

Pfizer Inc. (United States), Tolero Pharmaceuticals, Inc. (United States), FibroGen Inc. (United States), Vifor Pharma AG (Switzerland), Orphan Biovitrum AB (Switzerland), Therapure Biopharma Inc. (Canada), SBI Pharmaceuticals Co., Ltd. (Japan), Panacea Biotec Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Zydus Cadila (India) and 3SBio Inc. (China) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Chemotherapy Induced Anemia market by Type, Application and Region.

On the basis of geography, the market of Chemotherapy Induced Anemia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In 2019, Swedish Orphan Biovitrum AB (Sobi) acquired Dova Pharmaceuticals, Inc. This includes outstanding shares of Dova for USD 27.50 per share, net to the seller thereof in cash, without interest and subject to any applicable withholding taxes, plus one non-transferable Contingent Value Right (CVR) which entitles Dova shareholders to an additional USD 1.50 per share upon approval of Doptelet for use in Chemotherapy-Induced Thrombocytopenia by the US Food and Drug Administration.
In 2019, FibroGen Inc. has announced the first patient dosed in the company’s phase 2 clinical study of Roxadustat, a first in class hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of CIA in cancer patients receiving chemotherapy.


Market Drivers
  • Growing Awareness Regarding CIA, Its Demand for Early Recognition, Prevention, and Prompt Treatment
  • Increasing Availability of Chemotherapy Agents in the Developed As Well As Developing Region

Opportunities
  • Innovation in Identification Technology of CIA and Favorable Government Policies

Restraints
  • Lower Efficacy of the Treating Drugs Resulting in the Decreased Patient Compliance

Challenges
  • Approval for Drug and Technology from the Regulatory Bodies


Key Target Audience
Chemotherapy Induced Anemia Drug Manufacturers, Raw Material Suppliers, Research Institutes, Healthcare Organization, End-Use Industry and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Drug Type
  • Androxy Oral
  • Epoetin Alfa Injection
  • Epogen Injection
  • Procrit Injection
  • Aranesp injection
  • Others

By Type of Anemia
  • Mild Anemia
  • Moderate Anemia
  • Severe Anemia
  • Life-threatening Anemia

By Treatment Type
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Iron Supplementation
  • RBC Transfusions

By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Multispecialty Clinics
  • Cancer Research Centers
  • Cancer Rehabilitation Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Awareness Regarding CIA, Its Demand for Early Recognition, Prevention, and Prompt Treatment
      • 3.2.2. Increasing Availability of Chemotherapy Agents in the Developed As Well As Developing Region
    • 3.3. Market Challenges
      • 3.3.1. Approval for Drug and Technology from the Regulatory Bodies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chemotherapy Induced Anemia, by Drug Type, Type of Anemia, Treatment Type, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Chemotherapy Induced Anemia (Value)
      • 5.2.1. Global Chemotherapy Induced Anemia by: Drug Type (Value)
        • 5.2.1.1. Androxy Oral
        • 5.2.1.2. Epoetin Alfa Injection
        • 5.2.1.3. Epogen Injection
        • 5.2.1.4. Procrit Injection
        • 5.2.1.5. Aranesp injection
        • 5.2.1.6. Others
      • 5.2.2. Global Chemotherapy Induced Anemia by: Type of Anemia (Value)
        • 5.2.2.1. Mild Anemia
        • 5.2.2.2. Moderate Anemia
        • 5.2.2.3. Severe Anemia
        • 5.2.2.4. Life-threatening Anemia
      • 5.2.3. Global Chemotherapy Induced Anemia by: Treatment Type (Value)
        • 5.2.3.1. Erythropoiesis-Stimulating Agents (ESAs)
        • 5.2.3.2. Iron Supplementation
        • 5.2.3.3. RBC Transfusions
      • 5.2.4. Global Chemotherapy Induced Anemia by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Ambulatory Surgical Centers
        • 5.2.4.3. Multispecialty Clinics
        • 5.2.4.4. Cancer Research Centers
        • 5.2.4.5. Cancer Rehabilitation Centers
      • 5.2.5. Global Chemotherapy Induced Anemia Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Chemotherapy Induced Anemia: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Tolero Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. FibroGen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Vifor Pharma AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Orphan Biovitrum AB (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Therapure Biopharma Inc. (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. SBI Pharmaceuticals Co., Ltd. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Panacea Biotec Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Dr. Reddy’s Laboratories Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Zydus Cadila (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. 3SBio Inc. (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Chemotherapy Induced Anemia Sale, by Drug Type, Type of Anemia, Treatment Type, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Chemotherapy Induced Anemia (Value)
      • 7.2.1. Global Chemotherapy Induced Anemia by: Drug Type (Value)
        • 7.2.1.1. Androxy Oral
        • 7.2.1.2. Epoetin Alfa Injection
        • 7.2.1.3. Epogen Injection
        • 7.2.1.4. Procrit Injection
        • 7.2.1.5. Aranesp injection
        • 7.2.1.6. Others
      • 7.2.2. Global Chemotherapy Induced Anemia by: Type of Anemia (Value)
        • 7.2.2.1. Mild Anemia
        • 7.2.2.2. Moderate Anemia
        • 7.2.2.3. Severe Anemia
        • 7.2.2.4. Life-threatening Anemia
      • 7.2.3. Global Chemotherapy Induced Anemia by: Treatment Type (Value)
        • 7.2.3.1. Erythropoiesis-Stimulating Agents (ESAs)
        • 7.2.3.2. Iron Supplementation
        • 7.2.3.3. RBC Transfusions
      • 7.2.4. Global Chemotherapy Induced Anemia by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Ambulatory Surgical Centers
        • 7.2.4.3. Multispecialty Clinics
        • 7.2.4.4. Cancer Research Centers
        • 7.2.4.5. Cancer Rehabilitation Centers
      • 7.2.5. Global Chemotherapy Induced Anemia Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chemotherapy Induced Anemia: by Drug Type(USD Million)
  • Table 2. Chemotherapy Induced Anemia Androxy Oral , by Region USD Million (2015-2020)
  • Table 3. Chemotherapy Induced Anemia Epoetin Alfa Injection , by Region USD Million (2015-2020)
  • Table 4. Chemotherapy Induced Anemia Epogen Injection , by Region USD Million (2015-2020)
  • Table 5. Chemotherapy Induced Anemia Procrit Injection , by Region USD Million (2015-2020)
  • Table 6. Chemotherapy Induced Anemia Aranesp injection , by Region USD Million (2015-2020)
  • Table 7. Chemotherapy Induced Anemia Others , by Region USD Million (2015-2020)
  • Table 8. Chemotherapy Induced Anemia: by Type of Anemia(USD Million)
  • Table 9. Chemotherapy Induced Anemia Mild Anemia , by Region USD Million (2015-2020)
  • Table 10. Chemotherapy Induced Anemia Moderate Anemia , by Region USD Million (2015-2020)
  • Table 11. Chemotherapy Induced Anemia Severe Anemia , by Region USD Million (2015-2020)
  • Table 12. Chemotherapy Induced Anemia Life-threatening Anemia , by Region USD Million (2015-2020)
  • Table 13. Chemotherapy Induced Anemia: by Treatment Type(USD Million)
  • Table 14. Chemotherapy Induced Anemia Erythropoiesis-Stimulating Agents (ESAs) , by Region USD Million (2015-2020)
  • Table 15. Chemotherapy Induced Anemia Iron Supplementation , by Region USD Million (2015-2020)
  • Table 16. Chemotherapy Induced Anemia RBC Transfusions , by Region USD Million (2015-2020)
  • Table 17. Chemotherapy Induced Anemia: by End User(USD Million)
  • Table 18. Chemotherapy Induced Anemia Hospitals , by Region USD Million (2015-2020)
  • Table 19. Chemotherapy Induced Anemia Ambulatory Surgical Centers , by Region USD Million (2015-2020)
  • Table 20. Chemotherapy Induced Anemia Multispecialty Clinics , by Region USD Million (2015-2020)
  • Table 21. Chemotherapy Induced Anemia Cancer Research Centers , by Region USD Million (2015-2020)
  • Table 22. Chemotherapy Induced Anemia Cancer Rehabilitation Centers , by Region USD Million (2015-2020)
  • Table 23. South America Chemotherapy Induced Anemia, by Country USD Million (2015-2020)
  • Table 24. South America Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 25. South America Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 26. South America Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 27. South America Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 28. Brazil Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 29. Brazil Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 30. Brazil Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 31. Brazil Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 32. Argentina Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 33. Argentina Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 34. Argentina Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 35. Argentina Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 36. Rest of South America Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 37. Rest of South America Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 38. Rest of South America Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 39. Rest of South America Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 40. Asia Pacific Chemotherapy Induced Anemia, by Country USD Million (2015-2020)
  • Table 41. Asia Pacific Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 42. Asia Pacific Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 43. Asia Pacific Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 44. Asia Pacific Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 45. China Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 46. China Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 47. China Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 48. China Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 49. Japan Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 50. Japan Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 51. Japan Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 52. Japan Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 53. India Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 54. India Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 55. India Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 56. India Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 57. South Korea Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 58. South Korea Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 59. South Korea Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 60. South Korea Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 61. Taiwan Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 62. Taiwan Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 63. Taiwan Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 64. Taiwan Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 65. Australia Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 66. Australia Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 67. Australia Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 68. Australia Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 73. Europe Chemotherapy Induced Anemia, by Country USD Million (2015-2020)
  • Table 74. Europe Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 75. Europe Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 76. Europe Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 77. Europe Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 78. Germany Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 79. Germany Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 80. Germany Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 81. Germany Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 82. France Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 83. France Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 84. France Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 85. France Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 86. Italy Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 87. Italy Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 88. Italy Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 89. Italy Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 90. United Kingdom Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 91. United Kingdom Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 92. United Kingdom Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 93. United Kingdom Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 94. Netherlands Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 95. Netherlands Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 96. Netherlands Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 97. Netherlands Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 98. Rest of Europe Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 99. Rest of Europe Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 100. Rest of Europe Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 101. Rest of Europe Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 102. MEA Chemotherapy Induced Anemia, by Country USD Million (2015-2020)
  • Table 103. MEA Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 104. MEA Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 105. MEA Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 106. MEA Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 107. Middle East Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 108. Middle East Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 109. Middle East Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 110. Middle East Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 111. Africa Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 112. Africa Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 113. Africa Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 114. Africa Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 115. North America Chemotherapy Induced Anemia, by Country USD Million (2015-2020)
  • Table 116. North America Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 117. North America Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 118. North America Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 119. North America Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 120. United States Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 121. United States Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 122. United States Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 123. United States Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 124. Canada Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 125. Canada Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 126. Canada Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 127. Canada Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 128. Mexico Chemotherapy Induced Anemia, by Drug Type USD Million (2015-2020)
  • Table 129. Mexico Chemotherapy Induced Anemia, by Type of Anemia USD Million (2015-2020)
  • Table 130. Mexico Chemotherapy Induced Anemia, by Treatment Type USD Million (2015-2020)
  • Table 131. Mexico Chemotherapy Induced Anemia, by End User USD Million (2015-2020)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Chemotherapy Induced Anemia: by Drug Type(USD Million)
  • Table 144. Chemotherapy Induced Anemia Androxy Oral , by Region USD Million (2021-2026)
  • Table 145. Chemotherapy Induced Anemia Epoetin Alfa Injection , by Region USD Million (2021-2026)
  • Table 146. Chemotherapy Induced Anemia Epogen Injection , by Region USD Million (2021-2026)
  • Table 147. Chemotherapy Induced Anemia Procrit Injection , by Region USD Million (2021-2026)
  • Table 148. Chemotherapy Induced Anemia Aranesp injection , by Region USD Million (2021-2026)
  • Table 149. Chemotherapy Induced Anemia Others , by Region USD Million (2021-2026)
  • Table 150. Chemotherapy Induced Anemia: by Type of Anemia(USD Million)
  • Table 151. Chemotherapy Induced Anemia Mild Anemia , by Region USD Million (2021-2026)
  • Table 152. Chemotherapy Induced Anemia Moderate Anemia , by Region USD Million (2021-2026)
  • Table 153. Chemotherapy Induced Anemia Severe Anemia , by Region USD Million (2021-2026)
  • Table 154. Chemotherapy Induced Anemia Life-threatening Anemia , by Region USD Million (2021-2026)
  • Table 155. Chemotherapy Induced Anemia: by Treatment Type(USD Million)
  • Table 156. Chemotherapy Induced Anemia Erythropoiesis-Stimulating Agents (ESAs) , by Region USD Million (2021-2026)
  • Table 157. Chemotherapy Induced Anemia Iron Supplementation , by Region USD Million (2021-2026)
  • Table 158. Chemotherapy Induced Anemia RBC Transfusions , by Region USD Million (2021-2026)
  • Table 159. Chemotherapy Induced Anemia: by End User(USD Million)
  • Table 160. Chemotherapy Induced Anemia Hospitals , by Region USD Million (2021-2026)
  • Table 161. Chemotherapy Induced Anemia Ambulatory Surgical Centers , by Region USD Million (2021-2026)
  • Table 162. Chemotherapy Induced Anemia Multispecialty Clinics , by Region USD Million (2021-2026)
  • Table 163. Chemotherapy Induced Anemia Cancer Research Centers , by Region USD Million (2021-2026)
  • Table 164. Chemotherapy Induced Anemia Cancer Rehabilitation Centers , by Region USD Million (2021-2026)
  • Table 165. South America Chemotherapy Induced Anemia, by Country USD Million (2021-2026)
  • Table 166. South America Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 167. South America Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 168. South America Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 169. South America Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 170. Brazil Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 171. Brazil Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 172. Brazil Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 173. Brazil Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 174. Argentina Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 175. Argentina Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 176. Argentina Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 177. Argentina Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 178. Rest of South America Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 179. Rest of South America Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 180. Rest of South America Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 181. Rest of South America Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 182. Asia Pacific Chemotherapy Induced Anemia, by Country USD Million (2021-2026)
  • Table 183. Asia Pacific Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 184. Asia Pacific Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 185. Asia Pacific Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 186. Asia Pacific Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 187. China Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 188. China Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 189. China Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 190. China Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 191. Japan Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 192. Japan Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 193. Japan Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 194. Japan Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 195. India Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 196. India Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 197. India Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 198. India Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 199. South Korea Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 200. South Korea Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 201. South Korea Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 202. South Korea Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 203. Taiwan Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 204. Taiwan Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 205. Taiwan Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 206. Taiwan Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 207. Australia Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 208. Australia Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 209. Australia Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 210. Australia Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 211. Rest of Asia-Pacific Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 212. Rest of Asia-Pacific Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 214. Rest of Asia-Pacific Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 215. Europe Chemotherapy Induced Anemia, by Country USD Million (2021-2026)
  • Table 216. Europe Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 217. Europe Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 218. Europe Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 219. Europe Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 220. Germany Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 221. Germany Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 222. Germany Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 223. Germany Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 224. France Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 225. France Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 226. France Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 227. France Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 228. Italy Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 229. Italy Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 230. Italy Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 231. Italy Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 232. United Kingdom Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 233. United Kingdom Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 234. United Kingdom Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 235. United Kingdom Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 236. Netherlands Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 237. Netherlands Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 238. Netherlands Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 239. Netherlands Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 240. Rest of Europe Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 241. Rest of Europe Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 242. Rest of Europe Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 243. Rest of Europe Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 244. MEA Chemotherapy Induced Anemia, by Country USD Million (2021-2026)
  • Table 245. MEA Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 246. MEA Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 247. MEA Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 248. MEA Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 249. Middle East Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 250. Middle East Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 251. Middle East Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 252. Middle East Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 253. Africa Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 254. Africa Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 255. Africa Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 256. Africa Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 257. North America Chemotherapy Induced Anemia, by Country USD Million (2021-2026)
  • Table 258. North America Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 259. North America Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 260. North America Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 261. North America Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 262. United States Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 263. United States Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 264. United States Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 265. United States Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 266. Canada Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 267. Canada Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 268. Canada Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 269. Canada Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 270. Mexico Chemotherapy Induced Anemia, by Drug Type USD Million (2021-2026)
  • Table 271. Mexico Chemotherapy Induced Anemia, by Type of Anemia USD Million (2021-2026)
  • Table 272. Mexico Chemotherapy Induced Anemia, by Treatment Type USD Million (2021-2026)
  • Table 273. Mexico Chemotherapy Induced Anemia, by End User USD Million (2021-2026)
  • Table 274. Research Programs/Design for This Report
  • Table 275. Key Data Information from Secondary Sources
  • Table 276. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chemotherapy Induced Anemia: by Drug Type USD Million (2015-2020)
  • Figure 5. Global Chemotherapy Induced Anemia: by Type of Anemia USD Million (2015-2020)
  • Figure 6. Global Chemotherapy Induced Anemia: by Treatment Type USD Million (2015-2020)
  • Figure 7. Global Chemotherapy Induced Anemia: by End User USD Million (2015-2020)
  • Figure 8. South America Chemotherapy Induced Anemia Share (%), by Country
  • Figure 9. Asia Pacific Chemotherapy Induced Anemia Share (%), by Country
  • Figure 10. Europe Chemotherapy Induced Anemia Share (%), by Country
  • Figure 11. MEA Chemotherapy Induced Anemia Share (%), by Country
  • Figure 12. North America Chemotherapy Induced Anemia Share (%), by Country
  • Figure 13. Global Chemotherapy Induced Anemia share by Players 2020 (%)
  • Figure 14. Global Chemotherapy Induced Anemia share by Players (Top 3) 2020(%)
  • Figure 15. Global Chemotherapy Induced Anemia share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Tolero Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Tolero Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 21. FibroGen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. FibroGen Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Vifor Pharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Vifor Pharma AG (Switzerland) Revenue: by Geography 2020
  • Figure 25. Orphan Biovitrum AB (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Orphan Biovitrum AB (Switzerland) Revenue: by Geography 2020
  • Figure 27. Therapure Biopharma Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 28. Therapure Biopharma Inc. (Canada) Revenue: by Geography 2020
  • Figure 29. SBI Pharmaceuticals Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 30. SBI Pharmaceuticals Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 31. Panacea Biotec Limited (India) Revenue, Net Income and Gross profit
  • Figure 32. Panacea Biotec Limited (India) Revenue: by Geography 2020
  • Figure 33. Dr. Reddy’s Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 34. Dr. Reddy’s Laboratories Ltd. (India) Revenue: by Geography 2020
  • Figure 35. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 36. Zydus Cadila (India) Revenue: by Geography 2020
  • Figure 37. 3SBio Inc. (China) Revenue, Net Income and Gross profit
  • Figure 38. 3SBio Inc. (China) Revenue: by Geography 2020
  • Figure 39. Global Chemotherapy Induced Anemia: by Drug Type USD Million (2021-2026)
  • Figure 40. Global Chemotherapy Induced Anemia: by Type of Anemia USD Million (2021-2026)
  • Figure 41. Global Chemotherapy Induced Anemia: by Treatment Type USD Million (2021-2026)
  • Figure 42. Global Chemotherapy Induced Anemia: by End User USD Million (2021-2026)
  • Figure 43. South America Chemotherapy Induced Anemia Share (%), by Country
  • Figure 44. Asia Pacific Chemotherapy Induced Anemia Share (%), by Country
  • Figure 45. Europe Chemotherapy Induced Anemia Share (%), by Country
  • Figure 46. MEA Chemotherapy Induced Anemia Share (%), by Country
  • Figure 47. North America Chemotherapy Induced Anemia Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer Inc. (United States)
  • Tolero Pharmaceuticals, Inc. (United States)
  • FibroGen Inc. (United States)
  • Vifor Pharma AG (Switzerland)
  • Orphan Biovitrum AB (Switzerland)
  • Therapure Biopharma Inc. (Canada)
  • SBI Pharmaceuticals Co., Ltd. (Japan)
  • Panacea Biotec Limited (India)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Zydus Cadila (India)
  • 3SBio Inc. (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation